Serum hepcidin level is not an independent surrogate biomarker of disease activity or of radiographic progression in rheumatoid arthritis: Results from the ESPOIR cohort

Annals of the Rheumatic Diseases

Volumn 72, Issue 2, 2013, Pages 312-314

  Sellam, Jérémie ^a   Kotti, Salma ^a   Fellahi, Soraya ^b,c,d   Bastard, Jean Philippe ^b,c,d   Meyer, Magali ^a   Lioté, Frédéric ^e   Meyer, Olivier ^e   Simon, Tabassome ^a   Capeau, Jacqueline ^b,c,d   Berenbaum, Francis ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d HÔPITAL TENON   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HEPCIDIN; RHEUMATOID FACTOR;

ADULT; ANTIBODY TITER; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOOT RADIOGRAPHY; HAND RADIOGRAPHY; HEALTH ASSESSMENT QUESTIONNAIRE; HORMONE BLOOD LEVEL; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SHARP VAN DER HEIJDE SCORE;

ANTIMICROBIAL CATIONIC PEPTIDES; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; COHORT STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84872079699     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202119     Document Type: Letter

References (10)

1. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-6.
2. van Santen S, van Dongen-Lases ED, de Vegt F, et al. Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in anemic rheumatoid arthritis patients. Arthritis Rheum 2011;63:3672-80.
3. Abdel-Khalek MA, El-Barbary AM, Essa SA, et al. Serum hepcidin: a direct link between anemia of inflammation and coronary artery atherosclerosis in patients with rheumatoid arthritis. J Rheumatol 2011;38:2153-9.
4. Jayaranee S, Sthaneshwar P, Sokkalingam S. Serum prohepcidin concentrations in rheumatoid arthritis. Pathology 2009;41:178-82.
5. Demirag MD, Haznedaroglu S, Sancak B, et al. Circulating hepcidin in the crossroads of anemia and inflammation associated with rheumatoid arthritis. Intern Med 2009;48:421-6.
6. Kim HR, Kim KW, Yoon SY, et al. Serum pro-hepcidin could reflect disease activity in patients with rheumatoid arthritis. J Korean Med Sci 2010;25:348-52.
7. Frazer DM, Anderson GJ. Hepcidin compared with prohepcidin: an absorbing story. Am J Clin Nutr 2009;89:475-6.
8. Sasu BJ, Li H, Rose MJ, et al. Serum hepcidin but not prohepcidin may be an effective marker for anemia of inflammation (AI). Blood Cells Mol Dis 2010;45:238-45.
9. Combe B, Benessiano J, Berenbaum F, et al. The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007;74:440-5.
10. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2012;69:1580-8.